FeaturedMedia Release
Race to present on 29 July at IRD Invest
Race Oncology Limited (ASX:RAC) is pleased to announce that Dr Daniel Tillett will present at
FeaturedMedia ReleaseUncategorized
Race reports impressive 40% response in Phase II Bisantrene AML Trial
On 16 July 2020, Race was pleased to report results of the investigator led Phase II trial of
FeaturedMedia Release
Changing of the guard at Race
Dr. Peter Molloy has decided to step down as Managing Director and Chief Executive Officer at Race.
FeaturedMedia Release
Race starts preclinical breast cancer study for Bisantrene
Race Oncology has entered into a collaborative preclinical research program with The University
FeaturedMedia Release
Race raises A$1.8 million, appoints Non-Executive Chairman
Race has received firm commitments for A$1.8 million (before costs) in new equity funding via a
FeaturedMedia Release
Professor Borje Andersson appointed Director of Race
Race Oncology Limited is pleased to announce that Professor Borje Andersson has been appointed
FeaturedMedia Release
Prof Borje Andersson to Chair RAC Clinical Advisory Board
Race Oncology is pleased to announce that Professor Borje Andersson has agreed to chair Race’s
FeaturedMedia Release
Race reveals new strategy for cancer drug Bisantrene
Race Oncology has revealed its new “5 Path” clinical development strategy for its cancer drug,
FeaturedMedia Release
Dr Daniel Tillett joins Race Board
Prominent biotechnology investor and substantial Race shareholder, Dr Daniel Tillett, has
FeaturedMedia Release
Prominent biotech investor leads investment in Race
Race Oncology Limited is pleased to announce the successful completion of a $1.45 million